Oral Presentation:
Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa (Oral #O21)
- Presenter:
Tahseen Mozaffar , MD,Department of Neurology , University of California,Irvine, CA , U.S.A. - Date and time:
Saturday, October 7 ,7:45-8:45 a.m. E.T. - Location: PAC,
Charleston Area Convention Center
Poster Sessions:
Abstract Title: Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (Poster #P371)
- Presenter:
Kristl G. Claeys , MD, PhD, University Hospitals Leuven, Leuven,Belgium - Poster Session 3:
Friday, October 6 ,2:00-3:00 p.m. E.T. - Location: Ballroom A-C,
Charleston Area Convention Center
Abstract Title: Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #P373)
- Presenter:
Jordi Díaz-Manera , MD, PhD,John Walton Muscular Dystrophy Research Centre ,Newcastle upon Tyne,U.K. - Poster Session 3:
Friday, October 6 ,2:00-3:00 p.m. E.T. - Location: Ballroom A-C,
Charleston Area Convention Center
Abstract Title: Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials (Poster #P372)
- Presenter:
Barry J. Byrne , MD, PhD,University of Florida ,Gainesville, FL , U.S.A. - Poster Session 3:
Friday, October 6 ,2:00-3:00 p.m. E.T. - Location: Ballroom A-C,
Charleston Area Convention Center
Abstract Title: Disease burden, treatment patterns and healthcare resource utilization associated with Pompe disease in
- Presenter:
Christopher Lindberg , MD, Neuromuscular Centre,Sahlgrenska University Hospital ,Gothenburg, Sweden - Poster Session 3:
Friday, October 6 ,2:00-3:00 p.m. E.T. - Location: Virtual Platform
For more information on the
About
CONTACTS:
Investors:
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Head of
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
Source:
2023 GlobeNewswire, Inc., source